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Long-term endocrine therapy with either aromatase inhibitors (AIs) or tamoxifen may lead to endocrine resistance and disease
progression. Recent years have seen advances in our understanding of the complex biological mechanisms associated with resistance.
Growth factor signaling pathways appear to be upregulated in hormone-resistant tumours and interact with oestrogen-receptor (ER)
signaling, which remains functional even after long-term endocrine deprivation. Signaling through the human epidermal and insulin-like
growth-factor receptor (HER and IGFR, respectively) pathways may promote ligand-independent ER gene transcription and stimulate
growth factor signaling. Therapeutic agents that inhibit these signal transduction pathways, when combined with AIs, may offer breast
cancer patients new hope for more robust, longer-term remissions. Preliminary data from phase II studies of combination therapies
are encouraging. There is a large programme of ongoing randomised, controlled trials, the results of which should pave the way for
integrating combination therapies into clinical practice. To identify which patients will respond best to particular combinations of
treatments, biomarkers and gene expression profiles are being investigated as predictors of sensitivity or resistance. In time, breast
cancer treatment will become truly individualised because physicians will be able to match patients with a variety of disease
phenotypes to optimal combination therapies.
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Aberrant oestrogen-receptor (ER) expression/functioning has been
implicated in the development of over 70% of breast cancers, the
most common malignancy among women in the US and in Europe.
Many, but not all patients with ER-positive (ERþ) disease
respond to hormonal therapy (e.g., tamoxifen, aromatase inhibi-
tors (AIs)), but a large number will ultimately develop resistance
with long-term treatment. There is evidence that peptide growth
factors and their downstream effectors may interact with ER
signaling to influence the sensitivity of breast cancer cells to
endocrine therapy, and thus may be important targets for novel
treatments.
Combining the most effective oestrogen-deprivation therapies
with new therapies that target oestrogen-independent signaling
pathways may increase the efficacy of breast cancer treatment.
Advances in methods of assessing biomarkers and gene expression
profiles that predict response to treatment may in the future allow
physicians to tailor novel combination therapies to individual
patients. This review summarises current knowledge about the
mechanisms of endocrine resistance, the scientific rationale for
combination therapy with AIs, and the clinical promise of this new
approach.
OVERCOMING ENDOCRINE THERAPY RESISTANCE
AND THE RATIONALE FOR COMBINATION THERAPY
Endocrine therapy is the treatment of choice for hormone-
sensitive breast cancer; however, over time many patients become
resistant as tumours develop the ability to escape the antiproli-
ferative effects of endocrine therapy (Martin et al, 2003). Under-
standing the various mechanisms responsible for the development
of resistance to oestrogen deprivation will identify new therapeutic
strategies to enhance the efficacy of breast cancer treatment. Some
of the mechanisms of endocrine resistance involve oestrogen
hypersensitivity, upregulation of signal transduction pathways,
and crosstalk between upregulated signal transduction pathways
and the ER pathway.
Oestrogen hypersensitivity
Even following the development of endocrine resistance, ER
signaling may continue to play an important role in the
proliferation of breast cancer. Biopsies of tumours from the
majority of breast cancer patients who have relapsed on tamoxifen
show a functional ER (Johnston et al, 1997), and women who have
become refractory to tamoxifen respond to further endocrine
manipulation with the ERa downregulator fulvestrant (Dowsett
et al, 2005a), indicating that ER-mediated signaling remains
functional even in the setting of endocrine resistance. In vitro
studies with long-term oestrogen-deprived cells (LTED), a line of
MCF7 breast cancer cells developed under oestrogen-deprived
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endocrine deprivation by becoming hypersensitive to oestradiol
doses as low as 10
 12 M (Martin et al, 2003, Santen et al, 2005).
Data from this preclinical model suggest that resistance to AIs may
be due to acquired hypersensitivity to low oestradiol levels.
Crosstalk between ER and growth-signaling pathways
Adaptive upregulation of growth-signaling pathways leading to
ligand-independent ER gene transcription may also lead to
endocrine resistance (Figure 1). The epidermal growth-factor
receptor (EGFR) and the human epidermal growth-factor receptor
2 (HER-2) become upregulated in response to endocrine depriva-
tion or tamoxifen treatment (Knowlden et al, 2003; Martin et al,
2003) and are associated with disease progression, poor prognosis
and resistance to tamoxifen (Kurokawa et al, 2000; Knowlden et al,
2003).
Activation of EGFR or HER2 stimulates two major intracellular
kinase signaling cascades – the ras-raf-mitogenic-activated protein
kinase (MAPK) pathway and the phosphatidylinositol 3-kinase
(PI3K)/Akt pathway. These pathways activate downstream effectors,
which phosphorylate and activate ERa and its coactivators (e.g.,
A1B1). In turn, the activation of ERa stimulates the production of
growth factors (e.g., TGFa) and growth-factor signaling, creating a
synergistic, self-reinforcing TGFa-ER autocrine loop (Knowlden
et al, 2003). Over time, ER signaling may become dependent on
these alternate signaling pathways, allowing cells to bypass normal
endocrine responsiveness.
Recent evidence confirms the causal link between activated
MAPK and PI3K pathways and the development of endocrine
resistance. Studies using the previously mentioned LTED cells as
well as TAMR cells, a tamoxifen-resistant cell line generated by
continuous growth of MCF7 cells in tamoxifen containing media
for 4–6 months, show adaptive upregulation of EGFR and HER2
with resulting activation of the downstream effector, MAPK
(Knowlden et al, 2003; Martin et al, 2003). In turn, activated
MAPK may phosphorylate the ER at Ser118 leading to ligand-
independent transcription of oestrogen responsive genes (Chen
et al, 2002). Blocking EGFR signaling (using gefitinib) reduces
active MAPK and inhibits proliferation of tamoxifen resistant
breast cancer cells (Knowlden et al, 2003), while the MAPK
inhibitor, U0126, partially restores tamoxifen sensitivity (Kurokawa
et al, 2000). Hypersensitive LTED cells also show increased levels of
Akt and mTOR (mammalian target of rapamycin), and dual
inhibition of MAPK and mTOR reverses oestrogen hypersensitivity
(Santen et al, 2005). Similarly, increased IGF1R signaling has been
observed in response to long-term oestrogen deprivation (Martin
et al, 2005).
In summary, growth factor signaling, via EGFR, HER2 or IGF1R,
becomes upregulated with the development of endocrine resistance
and may lead to ligand-independent ER gene transcription. The
synergistic interaction between the ER pathway and growth-
signaling pathways promotes hormone resistance and disease
progression. Various signal transduction inhibitors (STIs), that
target the extracellular and intracellular domains of EGFR, HER2
and IGFR, are in development. These new therapies, in combina-
tion with potent ER inhibitors, may prevent or delay endocrine
resistance and improve outcomes for women with ERþ breast
cancer.
COMBINATION THERAPY WITH AN AI:
PRECLINICAL AND CLINICAL DATA
Growth-factor receptor inhibitors
EGFR inhibitors Gefitinib and erlotinib block the intracellular
tyrosine kinase (TK) domain of EGFR by competitively binding to
the receptor’s adenosine triphosphate (ATP) site. In vitro data
have shown that TAMR and LTED cells are more sensitive to
gefitinib than the wild-type endocrine-sensitive MCF-7 cells
(Knowlden et al, 2003; Martin et al, 2003).
Clinical studies of gefitinib and erlotinib monotherapy in
unselected breast cancer patients have generally produced
disappointing results; however, a phase II study of gefitinib
monotherapy in ERþ tamoxifen-resistant patients demonstrated
antitumour activity (Robertson et al, 2003), confirming the in vitro
observations that gefitinib’s efficacy may be primarily in the
endocrine-resistant setting. Neoadjuvant single-agent gefitinib and
gefitinib combined with the AIs anastrozole effectively reduced
the size of breast tumours and levels of ER phosphorylation in
previously untreated patients with ER/EGFR positive disease, with
the combination treatment outperforming gefitinib alone in terms
of reduction in tumour proliferation rate as measured by Ki67
(Polychronis et al, 2005). In contrast another phase II study of
anastrazole in combination with gefitinib in patients with ERþ
advanced disease who had previously failed hormonal therapy
showed a lack of robust antitumour activity (Mita et al, 2005).
However the inclusion criteria for these two studies differed. Mita’s
trial did not screen for EGFR. In contrast, Polychronis’ study
required both ER and EGFR positivity as inclusion criteria which
may have enriched the patient population and could explain their
positive results. There are a number of phase II trials underway
evaluating the combination of gefinitib and AIs in metastatic
breast cancer (Table 1).
HER2 inhibitors 15–20% of breast cancers overexpress HER2
and data from neoadjuvant trials have shown that these tumours
may be relatively resistant to tamoxifen but remain sensitive to
AIs (Ellis et al, 2001). Thus, for hormone-resistant breast cancer,
particularly for ERþ tumours that overexpress HER-2, combining
AIs with HER-2 inhibitors may be a more effective treatment
approach. It is a common misconception that most HER-2þ
tumours are ER-negative. While a greater proportion of ER  than
ERþ tumours are HER2þ, the greater absolute number of ERþ
tumours results in similar proportions of HER2þ tumours being
ERþ and ER . This is illustrated by 50% of patients enrolled in
the recent adjuvant trastuzumab clinical trials being either ERþ
or progesterone-receptorþ.
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Figure 1 A model for endocrine resistance and its treatment: crosstalk
between growth-factor receptor and ER pathways. Increased growth factor
signaling may contribute to endocrine resistance by directly activating ER
and leading to the transcription of oestrogen-related genes. Novel
therapies can target a number of steps along this dysregulated signaling
pathway and may therefore have an important role in the treatment of
endocrine resistant breast cancer.
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reduces downstream MAPK/ERK1/2 signaling, and at least
partially reverses tamoxifen resistance in vitro (Kurokawa et al,
2000). Preliminary findings from phase II clinical trials of letrozole
and trastuzumab in patients with hormone-sensitive, HER-2–
positive metastatic breast cancer revealed that the combination
was well tolerated and had a clinical benefit rate of 50% with
durable responses in 25% of the patients (Marcom et al, 2005
ASCO).
There are several ongoing nonrandomised phase II trials
examining the efficacy of combining trastuzumab and AIs, and a
phase III randomised, controlled trial comparing anastrozole with
and without trastuzumab (Table 1).
Combined EGFR and HER2 inhibitors Lapatinib is a dual oral TK
inhibitor (TKI) of EGFR and HER-2 and thus may have a greater
anticancer effect than therapies that target only one of these
receptors. The combination of lapatinib and tamoxifen effectively
blocked cell cycle progression in vitro and showed significant
antitumour activity in vivo in tamoxifen-resistant tumour
xenografts (Chu et al, 2005).
Treatment with single-agent lapatinib resulted in impressive
partial response and stable disease rates of 28 and 40%,
respectively, among 60 patients with previously untreated HER-
2þ metastatic breast cancer (Gomez et al, 2005), and a large phase
III trial exploring the efficacy of lapatinib in combination with
letrozole is underway (Table 1). The combination of letrozole with
AEE788, a dual TKI of EGFR/HER-2 and inhibitor of the vascular
endothelial growth factor (VEGF) receptor is also being investi-
gated.
Imatinib mesylate, a TKI of platelet-derived growth factor
(PDGF) and c-Kit, has demonstrated an antiproliferative effect in a
number of breast cancer cell lines but is ineffective as mono-
therapy in metastatic breast cancer (Modi et al, 2005). Small
nonrandomised phase II trials are exploring the efficacy of
combining imatinib with letrozole.
Table 1 Current, recently closed and planned randomized, controlled trials of signal transduction inhibitors and antiestrogens in combination with AI in
breast cancer
Trial name/sponsor Treatments Study phase Patients (N) Population
Monoclonal antibodies
B016216/Roche ANA7trastuzumab II/III 202 First/second line; ER+/HER-2+
CFEM 345C2403/Novartis LET7trastuzumab IV NR First/second line; ER+/HER-2+
EU-20527 LET7trastuzumab II 30–40 Second line; ER+/HER-2+
Pharmacia-NU-01B4 EXE7trastuzumab II 18–60 First/second line; ER+/HER-2+
CC#037518 LET+bevacizumab II NR First line
UAB 0467 LET+bevacizumab II 25 Neoadjuvant
Tyrosine kinase inhibitors
Trial 223 (Europe) ANA7gefitinib II 185 Neoadjuvant
CTRC, San Antonio ANA7gefitinib II 78 Second line
AstraZeneca 0713 ANA7gefitinib II 174 First/second line
EORTC 10021 ANA7gefitinib II 108 First line
ECOG 4101 ANA+gefitinib+vs FUL+gefitinib II 106 First/second line
GSK EGFR30008 LET7lapatinib III 760 First/second line
VICC BRE 0303 LET7erlotinib II 150 Second line
Farnesyl transferase inhibitors
JJPRD R115777-INT-22 LET7tipifarnib II 108 Second line
CWRU-JJPR-1102 (Ireland Cancer Center) LET7tipifarnib II 120 Second line
SCH 66336 ANA7lonafarnib II 110 First line
UCLA-0403073-01 (JCCC/NCI) ANA7lonafarnib II 110 First line
mTOR inhibitors
Wyeth Ayerst LET7temsirolimus II 90 First/second line
Ireland Cancer Center LET7temsirolimus II 108 Second line
Wyeth Ayerst 3066A1-303 LET7temsirolimus III 1236 First line
Novartis LET7everolimus II/III 600 First line
Novartis CRAD001C223 LET7everolimus II 212 Neoadjuvant
Antiestrogens
SOFEA ANA+FUL vs FUL vs EXE III 750 Postnonsteroidal AI
FACT ANA7FUL III 558 First line
SWOG-S0226 ANA7FUL III 690 First line
FIRST ANA7FUL II 200 First line
D6997C00057 ANA7FUL II 120 Neoadjuvant
CAT Study LET vs atamestane+toremifene III 842 First line
OSU-0494 EXE7FUL II 40 First/Second line
EFECT EXE vs FUL III 660 Postnonsteroidal AI
Note: TAM¼tamoxifen; ANA¼anastrozole; LET¼letrozole; FUL¼fulvestrant; EXE¼exemestane; NR¼not reported; ER+¼oestrogen receptor-positive; EGFR¼epidermal
growth-factor receptor; HER-2+¼human epidermal growth-factor receptor 2; AI¼aromatase inhibitor. CALGB¼Cancer and Leukemia Group B. CFEM¼Clinical (Research
with) Femara. CTRC¼Cancer Therapy & Research Center. ECOG¼Eastern Cooperative Oncology Group. EFECT¼The Evaluation of Faslodex and Exemstane Clinical Trial.
EORTC¼European Organization for Research and Treatment of Cancer. FACT¼The Faslodex and Arimidex in Combination Trial. JCCC/NCI¼Jonsson Comprehensive
Cancer Center/National Cancer Institute. J&J PRD¼Johnson & Johnson Pharmaceutical Research & Development. SCH¼Schering Plough. SOFEA¼Study of Faslodex vs
Exemestane with or without Arimidex. SWOG¼Southwest Oncology Group. UAB¼University of Alabama. UCLA¼University of California at Los Angeles.
VICC¼Vanderbilt-Ingram Cancer Center.
Combination therapy with AIs
A Leary and M Dowsett
663
British Journal of Cancer (2006) 95(6), 661–666 & 2006 Cancer Research UKmTOR inhibitors
The PI3K/Akt pathway interacts with ERa and is often aberrantly
upregulated in breast cancers, therefore a promising therapeutic
strategy is to inhibit the molecular target of rapamycin (mTOR), a
key downstream effector of the PI3K enzyme. Preclinical studies
have supported the activity of rapamycin analogues CCI 779
(temsirolimus) and RAD-001 (everolimus) in breast cancer cells
with activated Akt and showed that the addition of everolimus
reduced proliferation by a further 50% compared with letrozole
alone (Farmer et al, 2005).
Several randomised, controlled trials are underway to determine
the efficacy and safety of letrozole with temsirolimus or everolimus
in ERþ breast cancer (Table 1). One of these studies utilises a
two-stage design whereby biomarkers of response to the combina-
tion of letrozole and everolimus will be identified in a phase II
neoadjuvant trial, and based on these biomarkers, patients will be
randomised to letrozole alone or letrozole and everolimus as first-
line therapy in a subsequent phase III trial. Unfortunately despite
encouraging preclinical and early phase II data (Carpenter et al,
2005), HORIZON, a large phase III trial exploring the efficacy of
the combination of letrozole and temsirolimus in metastatic ERþ
breast cancer was recently terminated after an independent interim
analysis reported that the combination showed no benefit over
letrozole alone.
Farnesyl transferase inhibitors
The ras proto-oncogene can activate downstream TK substrates
(e.g., MAPK, MAPK/ERK kinase (MEK)) that influence cell
proliferation, survival and apoptosis and has been implicated in
breast cancer (O’Regan and Khuri, 2004). Farnesyl transferase
inhibitors (e.g., tipifarnib, lonafarnib) were developed to inhibit
tumour growth by blocking farnesylation, the first step in ras
activation.
Both in vitro and in vivo studies have shown that tipifarnib
inhibits the growth of MCF-7 breast cancer tumours (O’Regan and
Khuri, 2004), and a subsequent phase II study reported clinical
benefit in 24% of women with endocrine-resistant metastatic
breast cancer (Johnston et al, 2003).
The modest clinical activity of FTI monotherapy and results
from an animal study, in which the combination of tipifarnib and
tamoxifen resulted in significantly greater tumour regression than
either tamoxifen or tipifarnib alone (Johnston et al, 2002), raised
the possibility that FTIs may be more effective in combination with
endocrine treatment. A number of phase II randomised, controlled
trials are currently exploring the potential efficacy of combining
tipifarnib or lonafarnib with AI therapies (Table 1). However, a
recently reported phase II randomised study of letrozole7tipi-
farnib in 121 women with tamoxifen resistant advanced breast
cancer demonstrated no benefit to the combination compared to
letrozole alone (Johnston et al, 2005). The reasons for these
disappointing results are unclear, however, they may stem from
the fact that the exact targets of FTIs are still poorly understood as
many intracellular proteins aside from ras require farnesylation.
Also, ras may be able to escape the inhibitory effect of FTIs by
developing compensatory geranylgeranylation, which may suggest
a role for dual geranylgeranyl transferase-1/farnesyl transferase
inhibitors.
Antiangiogenic agents
In order to grow beyond the size of 1–2mm, tumours need to
develop their own vasculature. This process, known as angio-
genesis and principally mediated via tumoural secretion of VEGF,
is critical to tumour survival and has therefore emerged as an
attractive anticancer strategy. Bevacizumab, a humanised mono-
clonal antibody directed against all active isoforms of VEGF, does
not appear to be effective as a single agent in breast cancer but may
enhance efficacy when combined with other treatments. Preclinical
investigations suggest that oestrogen may have proangiogenic
effects by stimulating VEGF secretion, while VEGF receptor
signaling may contribute to endocrine resistance (Ryden et al,
2005, 142). These findings would suggest that targeting both
oestrogen signaling in breast cancer cells, as well as the associated
tumour vasculature may provide a more effective therapeutic
strategy. Preliminary results indicate that the combination of
bevacizumab and letrozole is well tolerated in patients with ERþ
metastatic breast cancer and resulted in stable disease in six out of
11 patients for 46months (Traina et al, 2005).
A number of new orally available small molecule inhibitors of
the TK domain of the VEGFR are being developed. These include
PTK-787 (vatalanib), a selective inhibitor of the VEGF and PDGF
receptor TKs and SU11248 (sunitinib), a novel receptor TKI with
potential for both direct antitumour and antiangiogenic activity by
targeting kit and Fms-like TK 3(flt-3), as well as the VEGF and
PDGF receptors. In a phase II trial, single-agent sunitinib showed
activity in patients with advanced breast cancer (Miller et al, 2005).
The combination of AEE788 (a dual TKI of EGFR/HER-2 and
inhibitor of the VEGF receptor) and letrozole has been shown
to enhance growth inhibition in ERþ breast cancer cell lines
compared with either drug alone (Hauge-Evans et al, 2004), but
this activity may be restricted to tumours that overexpress EGFR
and/or HER-2. BAY43-9006 (sorafenib) is another multitargeted
antiangiogenic inhibitor of both RAF kinase and the VEGFR/
PDGFR-b signaling cascade; it is currently being investigated in a
phase I/II trial in combination with anastrozole.
Novel anti-oestrogens
As long-term treatment with an AI may cause acquired endocrine
resistance and hypersensitivity to low doses of oestradiol (Martin
et al, 2005; Santen et al, 2005), concomitant treatment with an
additional anti-oestrogen may improve efficacy. Fulvestrant is an
anti-oestrogen that leads to ER degradation and a phase II study
of fulvestrant in post-menopausal women with metastatic ERþ
breast cancer who had progressed on an AI demonstrated clinical
benefit (PR¼14%; SD¼20%)(Ingle et al, 2006). However,
preclinical data would suggest that combination rather than
sequential treatment may be a superior approach. Indeed, wild-
type MCF7 breast cancer cells are sensitive to fulvestrant, while
LTED cells that have become hypersensitive to oestrogen require
maximally suppressed oestradiol to be sensitive to fulvestrant
(Dowsett et al, 2005a); thus, combining an AI, which decreases
oestradiol to very low levels, with fulvestrant may have a
synergistic effect. This would suggest that in the setting of AI
resistance, there may be a rationale for adding a pure anti-
oestrogen rather than switching to it and the ongoing SOFEA trial
has been designed to address this question. It is a three arm
randomised study of fulvestrant vs anastrazoleþfulvestrant vs
exemestane (a steroidal AI) in women with metastatic breast
cancer who have progressed on a nonsteroidal AI.
ONGOING AND FUTURE TRIALS
The promise of new combinations with AI has led to the
development of a diverse programme of current and planned
randomised, controlled trials that are summarised in Table 1. In
addition to the plethora of current randomised, controlled trials,
various nonrandomised clinical trials will explore the potential
efficacy and safety of trastuzumab, bevacizumab, sorafenib, and
erlotinib in combination with an AI as first-line or second-line
therapy, and one trial will test the combination of anastrozole,
fulvestrant and gefinitib in the neoadjuvant setting.
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Advanced diagnostic tools are being developed to predict
sensitivity and resistance and allow for the optimisation of
treatment by tailoring therapies to individual patients.
Biomarkers
Efforts are underway to identify molecular predictors of sensitivity
or resistance to particular therapies by correlating various
biomarkers to treatment response. HER2 overexpression by
immunohistochemistry has been well validated as a predictor of
response to trastuzumab. While data suggest that HER2 upregula-
tion may confer resistance to tamoxifen (Kurokawa et al, 2000), it
does not appear to preclude response to AIs (Ellis et al, 2001). Ki67
is a marker of tumour proliferation and is becoming accepted as an
early indicator of sensitivity or resistance to endocrine therapy.
Indeed, changes in Ki67 as early as 2 weeks after initiation of
endocrine therapy accurately predicted long-term disease-free
survival in the adjuvant setting (Dowsett et al, 2005b). Other
biomarkers such as ER and progesterone-receptor expression,
pAKT and pMAPK can be correlated with changes in Ki67 to gain
insight into the differential biological characteristics of tumours
that are sensitive or resistant to treatment. A novel strategy is the
short presurgical trial design, in which treatment-naı ¨ve patients
receive a 10- to 14-day treatment with an investigative agent
between the time of diagnosis and surgery, to identify in vivo
surrogate markers of resistance or sensitivity to treatment.
Gene profiling assays
A number of recent retrospective studies have used microarray
technology to identify the gene expression profiles of tumours that
are sensitive or resistant to tamoxifen (Jansen et al, 2005) or AIs
monotherapy (MacKay et al, 2005). Future studies will determine
whether these genomic signatures can be applied to early breast
cancer patients to identify the most effective adjuvant endocrine
treatment. In the future, it may be possible to predict long-term
responses to treatment based on the molecular profile of a patient’s
pretreatment gene expression and/or changes in gene expression
following a brief treatment period. In fact, preliminary data
suggests that gene clusters separating pretreatment and post-
treatment biopsies may be a better indicator of biological response
than changes in Ki67 (MacKay et al, 2005).
A number of gene expression profiles have already been
developed for the prognostication of women with newly diagnosed
breast cancer in an effort to improve on currently available
clinicopathological parameters and identify those at low-risk who
may be spared adjuvant chemotherapy. Additional refinement and
validation are needed before these tests can be fully integrated into
patient care and large-scale trials are planned (e.g., MINDACT,
TAILORx) to validate the use of these new diagnostic tools.
CONCLUSIONS
Although tamoxifen was once the gold standard endocrine
treatment for ERþ breast cancer, AIs have emerged as a viable
alternative and are challenging tamoxifen as the treatment of
choice for both early and advanced breast cancer in postmeno-
pausal women with ERþdisease. However a number of women
invariably develop resistance to oestrogen deprivation and relapse.
Several models, supported by preclinical data, have been proposed
to explain the mechanisms of hormone resistance including
oestrogen hypersensitivity and aberrant growth signaling path-
ways. This more profound understanding of the biology of
resistance has led to the rational design of studies combining
AIs with STIs or anti-oestrogens; these combinations offer the
possibility of delaying or overcoming hormone resistance at low
toxicity costs. Prior to being introduced into large clinical trials,
novel combination therapies should be supported by in vitro
models, however, healthy skepticism should be maintained since
robust preclinical data may not always translate into meaningful
clinical benefit, as illustrated by the recent disappointing results
of combination trials with an FTI or an mTOR inhibitor. These
observations further underscore the crucial need for early phase
I/II trials to include parallel biological studies examining the
association of protein or gene expression profiles with treatment
response as enrolling an unselected population into large phase III
trials may dilute the potential beneficial effects of a specific
combination for a subset of patients. In the future, breast cancer
therapy may be tailored to each patient to maximise benefits. This
individualised treatment will only be possible by identifying and
validating biomarkers that accurately predict which patients are
most likely to benefit from various combined endocrine and STI
therapies and the results of the ongoing combination trials will
define whether regimens combining AIs with novel targeted agents
should become an integral part of the next generation of breast
cancer treatment.
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